Australia, Aug. 27 -- Ocugen Inc., owns the trademark (2519937) for 'SYTHEIA' till Feb. 6, 2035.
Status: registered:
Registered/protected
Classes: 5 [Gene therapy products, namely, genetically engineered tissues for transplant purposes; Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases; Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases; Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa; Gene therapy products, namely, recombinant DNA for treating ocular diseases; Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa; Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration.] and 5 [Gene therapy products, namely, genetically engineered tissues for transplant purposes;Gene therapy products, namely, recombinant adeno-associated virus (rAAV) vector for treating ocular diseases;Gene therapy products, namely, rAAV vector for treating Retinitis Pigmentosa;Gene therapy products, namely, recombinant nucleic acid for treating ocular diseases;Gene therapy products, namely, recombinant nucleic acid for treating Retinitis Pigmentosa;Gene therapy products, namely, recombinant DNA for treating ocular diseases;Gene therapy products, namely, recombinant DNA for treating Retinitis Pigmentosa;Gene therapy products, namely, rAAV for treating ocular diseases such as Leber congenital amaurosis (LCA), retinitis pigmentosa, enhance S-cone syndrome, Goldmann Favre syndrome, rod-cone dystrophy Bardet-Biedl Syndrome, Achromatopsia, Best Disease (vitelliform macular degeneration), Bardet-Biedl Syndrome, Choroideremia, Macular Degeneration, Stargardt Disease, X-Linked Retinoschisis (XLRS), X-Linked Retinitis Pigmentosa (XLRP), Usher Syndrome, cone-rod dystrophy, Dry-Age related macular degeneration, and wet-Age related macular degeneration]
Type of Mark: Word
Date of Acceptance: Feb. 7
Registration Advertised: Aug. 26
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2519937.
Disclaimer: Curated by HT Syndication.
